Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund Levin Capital Is Betting On These Stocks

In a new filing with the Securities and Exchange Commission, John Levin‘s Levin Capital Strategies disclosed a new passive stake in New Senior Investment Group Inc (NYSE:SNR), a company that went public at the beginning of November. The fund disclosed holding 3.94 million shares of the company, which represent 5.96% of the company’s outstanding common stock. In a separate filing, Levin reported slightly trimming its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) to 1.16 million shares from 1.18 million shares disclosed in its latest 13F filing; the passive stake amasses 4.9% of the company.

Bio-Rad Laboratories

New Senior Investment Group Inc (NYSE:SNR) is a real estate investment trust that has been recently spun-off from Newcastle Investment Corp. (NYSE:NCT). At the end of October shareholders received one share of New Senior Investment for every share of Newcastle. At the end of September, Levin Capital held around 5.93 million shares of Newcastle Investment Corp.

New Senior Investment Group Inc (NYSE:SNR) holds a portfolio of senior housing properties in the US. The company’s portfolio is separated into Managed Properties and Triple Net Lease Properties, which New Senior Investment Group Inc (NYSE:SNR) leases to tenants. The stock of the REIT has decreased by 10% since it began trading.

On the other hand, in Bio-Rad Laboratories, Inc. (NYSE:BIO) Levin has been a long-term shareholder. The fund first disclosed holding around 93,600 shares as of the end of June 2010, while the stock gained more than 35% since then. The company is a $3.50 billion manufacturer and supplier of products for science research, healthcare, analytical chemistry markets. So far this year Bio-Rad Laboratories, Inc. (NYSE:BIO)’s stock lost around 3% as the company reported a slight increase in financial results. Its revenue for the third quarter appreciated by 5% on the year to $531 million, while its net income surged to $0.39 per share from a loss of $0.25 per share last year.

Overall investors have mixed sentiments regarding Bio-Rad Laboratories, Inc. (NYSE:BIO), as our data show. At the end of September, 26 funds held long positions in the company, up from 22 in the previous quarter, out of a total of more than 700 funds that we track. However, the value of the total number of shares held by these funds went down by $7.48 million to $476.38 million. John W. Rogers’ Ariel Investments is the largest shareholder among funds that we track, holding 1.07 million shares of the company as of the end of September.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!